Literature DB >> 1318622

Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract.

M B Mazanec1, M E Lamm, D Lyn, A Portner, J G Nedrud.   

Abstract

The protective efficacy of anti-Sendai virus IgA was compared to that of IgG after topical application of monoclonal antibodies (MAb) to the respiratory tract of mice. BALB/c mice were passively intranasally immunized with 50 microliters ascites containing equivalent ELISA titers of MAb 1 h before and 4 and 24 h after intranasal challenge with Sendai virus. Lung viral titers were determined by plaque assay 3 days following challenge. In most instances IgA MAb afforded equivalent protection to IgG MAb in that there was no significant difference in virus recovery from the lungs of animals treated with either IgA or IgG MAb, including subclasses of IgG. When IgA MAb was fractionated into monomers and oligomers, there was no inherent advantage to the oligomeric form with respect to passive protection against viral challenge. The data indicate that IgA and IgG antibodies are equally efficacious in protecting the airways from viral infection. The experiments suggest that the advantage of IgA for protecting mucosal surfaces, such as the respiratory tract, relates to the presence of a specialized mechanism for transporting oligomeric IgA across epithelial surfaces. The results also support the rationale for active mucosal immunization protocols designed to generate an IgA response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318622     DOI: 10.1016/0168-1702(92)90063-f

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  15 in total

Review 1.  Intranasal antibody prophylaxis for protection against viral disease.

Authors:  R Weltzin; T P Monath
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

2.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Authors:  C Bergquist; E L Johansson; T Lagergård; J Holmgren; A Rudin
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines.

Authors:  Robert Sealy; Richard J Webby; Jeri C Crumpton; Julia L Hurwitz
Journal:  Int Immunol       Date:  2012-11-08       Impact factor: 4.823

4.  CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.

Authors:  H Plotnicky-Gilquin; A Robert; L Chevalet; J F Haeuw; A Beck; J Y Bonnefoy; C Brandt; C A Siegrist; T N Nguyen; U F Power
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  CD4+ T cells support establishment of RSV-specific IgG and IgA antibody secreting cells in the upper and lower murine respiratory tract following RSV infection.

Authors:  Robert E Sealy; Sherri L Surman; Julia L Hurwitz
Journal:  Vaccine       Date:  2017-04-11       Impact factor: 3.641

6.  Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice.

Authors:  R Weltzin; S A Hsu; E S Mittler; K Georgakopoulos; T P Monath
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 7.  Biology of parainfluenza viruses.

Authors:  R Vainionpää; T Hyypiä
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

8.  Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs.

Authors:  Christopher W Seibert; Saad Rahmat; Jens C Krause; Dirk Eggink; Randy A Albrecht; Peter H Goff; Florian Krammer; J Andrew Duty; Nicole M Bouvier; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

Review 9.  Immunocompetent cells of the upper airway: functions in normal and diseased mucosa.

Authors:  P Brandtzaeg
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

10.  The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response.

Authors:  Antoine Minne; Jamila Louahed; Sybille Mehauden; Benoît Baras; Jean-Christophe Renauld; Rita Vanbever
Journal:  Immunology       Date:  2007-05-22       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.